The results are consistent with the data released earlier this year from the previous cohort of patients - slightly better than before - but that is comparing d/c data with 30 day follow up, so there may be an explanation for the difference in results. However, the lack of need for pacemaker post surgery of this type is encouraging (we, almost lack of - one patient out of 25+ is still encouraging).
Looking forward for the 30 day results, and hopefully the next phase of the testing can progress.
Ann: Positive Results from Interim Analysis of DurAVR EFS Trial, page-9
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$6.00 |
Change
-0.030(0.50%) |
Mkt cap ! $92.99M | |||
| Open | High | Low | Value | Volume |
| $6.01 | $6.03 | $5.84 | $85.53K | 14.32K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 333 | $6.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.25 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| AVR (ASX) Chart |